Drugs /

alendronate sodium

Back to Drugs List

Overview

NCI Definition [1]:
The sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced.

Clinical Trials

View Clinical Trials for alendronate sodium

Alendronate sodium has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating alendronate sodium, 1 is phase 1 (0 open).

BRCA1 Loss, BRCA1 Mutation, and BRCA2 Loss are the most frequent biomarker inclusion criteria for alendronate sodium clinical trials.

Breast lobular carcinoma in situ, ductal carcinoma in situ, and hereditary breast and ovarian cancer syndrome are the most common diseases being investigated in alendronate sodium clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Alendronate Sodium
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating alendronate sodium and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
alendronate monosodium salt, trihydrate, alendronate sodium, sodium, alendronate, alendronate sodium, adronat, onclast, mk 217, mk-217, binosto, alendronic acid monosodium salt trihydrate, mk217, alendronate, 129318-43-0, alendronate sodium (substance), alendros, fosamax, alendronate sodium, g-704650
NCIT ID [1]:
C973
SNOMED ID [1]:
F-61B95

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.